Neumora Therapeutics, Inc. Common Stock
HealthcareNASDAQ:NMRA · NASDAQ Global Select
+$0.00 today
Vol 0.72M · Avg 1.22M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-228.1%
avg -22.3%
ROIC
-151.8%
avg -60.7%
ROA
-124.0%
avg -54.9%
Analysis
ROA is currently the strongest return metric at -124.0% versus its period average of -54.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joshua Pinto | President | $2.10M | — | 41 | $57,783.00 | 0.03% |
Daljit Singh Aurora | Chief Operationg and development officer | $1.75M | — | 58 | $82,770.00 | 0.04% |
Jason G. Duncan | Chief Legal & Administrative Officer | $315,000.00 | — | 52 | $750,000.00 | 0.40% |
Paul Yeung | Senior Vice President of Clinical Development | — | — | — | $7.40M | 3.99% |
Stefan Bluemmers | Senior VP of Business Development & Portfolio Management | — | — | — | — | — |
Michael Lee Milligan | Chief Financial Officer & Principal Accounting Officer | — | — | 53 | $21,034.00 | 0.01% |
Carol Suh | Co-Founder & Chief Strategy Officer | — | — | 37 | — | — |
Pablo Gersberg | Chief Information Officer | — | — | — | — | — |
Amy Sullivan | Chief Human Resources Officer | — | — | — | — | — |
Nicholas Brandon | Chief Scientific Officer | — | — | 51 | — | — |
Lori Houle | Chief Technical Operations & Quality Officer | — | — | 59 | — | — |
Helen Rubinstein | Head of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$15.00M
Sells
5
$389,613.58
Net Sentiment
+$14.61M
Net buying
Most Active
Aurora Daljit Singh
2 transactions
Analysis
Insiders reported 3 buys worth $15.00M and 5 sells worth $389,613.58 over the last 12 months. That adds up to net buying of $14.61M. Aurora Daljit Singh was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Alumis Inc. Common Stock
NASDAQ:ALMS
$2.98B
RAPT Therapeutics, Inc.
RAPT
$959.26M
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$852.86M
Omeros Corporation
NASDAQ:OMER
$632.20M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$461.60M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
Autolus Therapeutics plc
NASDAQ:AUTL
$415.18M
Bicycle Therapeutics plc
NASDAQ:BCYC
$281.05M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$186.68M
ADC Therapeutics S.A.
NYSE:ADCT
$133.55M
Who manages NMRA?
Neumora Therapeutics, Inc. Common Stock (NMRA) lists 12 active executives. The top listed executive is Paul Yeung, Senior Vice President of Clinical Development.
Are NMRA insiders buying or selling?
Recent insider activity shows net buying of $4.08M.
Explore More
Continue the stock analysis
Jump to another research area for this company.